Kazia Therapeutics (KZIA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kazia Therapeutics presented promising data from a Phase 1 trial of EVT801, showing potential as a first-in-class VEGFR-3 inhibitor for treating high-grade serous ovarian cancer. The study identified a well-tolerated maximum dose and demonstrated encouraging signs of clinical activity, including a partial response in one patient and stable disease in 46% of participants. The company’s presentation at the 15th Biennial Ovarian Cancer Research Symposium has generated optimism for future developments in ovarian cancer therapy.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.